Share This Author
Ido expression by dendritic cells: tolerance and tryptophan catabolism
This review summarizes key recent developments and proposes a unifying model for the role of IDO in tolerance induction, including studies of mammalian pregnancy, tumour resistance, chronic infections and autoimmune diseases.
Prevention of allogeneic fetal rejection by tryptophan catabolism.
In 1953 Medawar pointed out that survival of the genetically disparate (allogeneic) mammalian conceptus contradicts the laws of tissue transplantation and suppresses T cell activity and defends itself against rejection.
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.
Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis.
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
- D. Munn, Ebrahim Shafizadeh, J. Attwood, I. Bondarev, A. Pashine, A. Mellor
- BiologyThe Journal of experimental medicine
- 3 May 1999
It is shown that monocytes that have differentiated under the influence of macrophage colony-stimulating factor acquire the ability to suppress T cell proliferation in vitro via rapid and selective degradation of tryptophan by IDO.
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.
- Madhav Sharma, B. Baban, D. Munn
- Biology, ChemistryThe Journal of clinical investigation
- 4 September 2007
It is hypothesized that IDO+ pDCs create a profoundly suppressive microenvironment within tumor-draining LNs via constitutive activation of Tregs, which was selectively lost when tumors were grown in IDO-deficient hosts.
Potential Regulatory Function of Human Dendritic Cells Expressing Indoleamine 2,3-Dioxygenase
A subset of human APCs that express indoleamine 2,3-dioxygenase (IDO) and inhibit T cell proliferation in vitro is described and it is suggested that these cells may represent a regulatory subset of APCs in humans.
Indoleamine 2,3 dioxygenase and metabolic control of immune responses.
Indoleamine 2,3-dioxygenase and tumor-induced tolerance.
Strategies to block Indoleamine 2,3-dioxygenase (IDO) might enhance the effectiveness of tumor immunotherapy.
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.
It is hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.